Wedbush Securities’s ProQR Therapeutics PRQR Stock Holding History

Wedbush Securities’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-10,720	Closed	-$35K	–	878
2017 Q4	$35K	Buy	+10,720	New	+$38.5K	﹤0.01%	831

Other funds holding PRQR

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wedbush Securities's PRQR Position: Q1 2018 in Review

Wedbush Securities sold out of ProQR Therapeutics (PRQR) in Q1 2018, closing a stake of 10,720 shares — an estimated $35K sold.

Wedbush Securities first reported a position in PRQR in Q4 2017 and held it in 1 quarter. The position peaked at $35K in Q4 2017. 25 funds tracked by Wall St. Rank hold PRQR as of Q1 2018.

Wedbush Securities reported no remaining ProQR Therapeutics position as of Q1 2018 after selling out during the quarter.
Wedbush Securities sold 10,720 ProQR Therapeutics shares in Q1 2018, an estimated $35K.
Wedbush Securities first reported a position in ProQR Therapeutics in Q4 2017 and held it in 1 quarter.
Wedbush Securities's ProQR Therapeutics position peaked at $35K in Q4 2017.
25 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2018.

Based on Wedbush Securities's 13F filing for Q1 2018, filed 1 May 2018.